surmount-1 trial tirzepatide obesity without diabetes For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The Tirzepatide for the Maintenance of
Description
Always seek the advice of your doctor/primary care provider before starting or changing treatment.
Frequently Asked Questions What are the primary differences in the mechanism of action between Tesofensine and GLP-1 agonists
Transl Sci
Understanding these can help in managing the side effects more effectively
Both medications reach peak effectiveness roughly the same time after starting the maximum maintenance dose
It may help curb appetite and reduce cravings, making it easier to maintain healthy eating habits
